Panagora Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Panagora Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-649	Closed	-$58K	–	2394
2018 Q1	$58K	Buy	649 +304	+88%	+$25.8K	﹤0.01%	1991
2017 Q4	$19K	Sell	345 -1,578	-82%	-$71.1K	﹤0.01%	2175
2017 Q3	$81K	Buy	1,923 +1,906	+11,212%	+$79.3K	﹤0.01%	1943
2017 Q2	$1K	Hold	17	–	–	﹤0.01%	2566
2017 Q1	$1K	Sell	17 -14,121	-100%	-$701K	﹤0.01%	2350
2016 Q4	$540K	Sell	14,138 -5,721	-29%	-$232K	﹤0.01%	1410
2016 Q3	$789K	Buy	+19,859	New	+$902K	﹤0.01%	1284
2016 Q1	–	Sell	-20,505	Closed	-$1.55M	–	2318
2015 Q4	$1.55M	Buy	20,505 +20,447	+35,253%	+$3.28M	0.01%	900
2015 Q3	$22K	Sell	58 -156	-73%	-$70.3K	﹤0.01%	2125
2015 Q2	$89K	Buy	+214	New	+$89.5K	﹤0.01%	1981

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Panagora Asset Management's LRMR Position: Q2 2018 in Review

Panagora Asset Management sold out of Larimar Therapeutics (LRMR) in Q2 2018, closing a stake of 649 shares — an estimated $58K sold.

Panagora Asset Management first reported a position in LRMR in Q2 2015 and held it in 10 quarters. The position peaked at $1.55M in Q4 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q2 2018.

Panagora Asset Management reported no remaining Larimar Therapeutics position as of Q2 2018 after selling out during the quarter.
Panagora Asset Management sold 649 Larimar Therapeutics shares in Q2 2018, an estimated $58K.
Panagora Asset Management first reported a position in Larimar Therapeutics in Q2 2015 and held it in 10 quarters.
Panagora Asset Management's Larimar Therapeutics position peaked at $1.55M in Q4 2015.
87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2018.

Based on Panagora Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.